Foodborne Illness

U.S. Navy to Fund Phase III Trial of Campylobacter Vaccine

Published in Vaccine Weekly, September 6th, 2000

Antex Biologics Inc. (ATXB), Gaithersburg, Maryland, announced that it has signed a Cooperative Research and Development Agreement (CRADA) with the U.S. Department of the Navy whereby the Navy will continue the clinical development of Antex's Campyvax.

Campyvax is a vaccine for the prevention of gastroenteritis, diarrhea, and Traveler's Disease caused by Campylobacter, a common pathogenic bacterium. Under the terms of this CRADA, Antex will supply vaccine and research and development support to the Navy, and the Navy will fund and conduct clinical trials through Phase III. Antex holds all intellectual property and marketing rights to Campyvax.

...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Vaccine Weekly

Source: Vaccine Weekly (2000-09-06)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry